U.S. Bans Imports From Fourth Ranbaxy Plant After Violations Found
This article was originally published in PharmAsia News
Executive Summary
Once again, Daiichi Sankyo's Ranbaxy Laboratories unit has no India facility capable of exporting drugs to its primary customer, the U.S.